{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:24:10Z","timestamp":1783056250715,"version":"3.54.6"},"reference-count":160,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Inflammatory bowel diseases (IBDs) are characterized by chronic inflammatory disorders that are a result of an abnormal immune response mediated by a cytokine storm and immune cell infiltration. Proinflammatory cytokine therapeutic agents, represented by TNF inhibitors, have developed rapidly over recent years and are promising options for treating IBD. Antagonizing interleukins, interferons, and Janus kinases have demonstrated their respective advantages in clinical trials and are candidates for anti-TNF therapeutic failure. Furthermore, the blockade of lymphocyte homing contributes to the excessive immune response in colitis and ameliorates inflammation and tissue damage. Factors such as integrins, selectins, and chemokines jointly coordinate the accumulation of immune cells in inflammatory regions. This review assembles the major targets and agents currently targeting proinflammatory cytokines and lymphatic trafficking to facilitate subsequent drug development.<\/jats:p>","DOI":"10.3390\/ph15091080","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:13:56Z","timestamp":1661904836000},"page":"1080","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing"],"prefix":"10.3390","volume":"15","author":[{"given":"Yijie","family":"Song","sequence":"first","affiliation":[{"name":"School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Yuan","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxi","family":"Xu","sequence":"additional","affiliation":[{"name":"Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"ref_1","unstructured":"(2020). The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol., 5, 17\u201330."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","article-title":"Immunopathogenesis of IBD: Current state of the art","volume":"13","author":"Fiocchi","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/ecco-jcc\/jjab029","article-title":"The Burden of Inflammatory Bowel Disease in Europe in 2020","volume":"15","author":"Zhao","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41590-019-0415-0","article-title":"Targeting immune cell circuits and trafficking in inflammatory bowel disease","volume":"20","author":"Neurath","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/MIB.0000000000000714","article-title":"Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases","volume":"22","author":"Chen","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00535-018-1449-z","article-title":"New treatment options for inflammatory bowel diseases","volume":"53","author":"Verstockt","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrrheum.2017.22","article-title":"Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases","volume":"13","author":"Croft","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_9","first-page":"325129","article-title":"Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease","volume":"2014","author":"Lebioda","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1136\/gutjnl-2019-318264","article-title":"Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling","volume":"69","author":"Koelink","year":"2019","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","article-title":"Construction and initial characterization of a mouse-human chimeric anti-TNF antibody","volume":"30","author":"Knight","year":"1993","journal-title":"Mol. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2020-322339","article-title":"First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn\u2019s disease: An open-label multicentre randomised controlled trial","volume":"71","author":"Jongsma","year":"2022","journal-title":"Gut"},{"key":"ref_13","unstructured":"Gerriets, V., Goyal, A., and Khaddour, K. (2022). Tumor Necrosis Factor Inhibitors. StatPearls, StatPearls Publishing."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/gutjnl-2016-312581","article-title":"Efficacy of adalimumab in patients with Crohn\u2019s disease and symptomatic small bowel stricture: A multicentre, prospective, observational cohort (CREOLE) study","volume":"67","author":"Bouhnik","year":"2018","journal-title":"Gut"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/MIB.0b013e3182a11958","article-title":"AVX-470: A novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease","volume":"19","author":"Bhol","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/ecco-jcc\/jjw036","article-title":"AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial","volume":"10","author":"Harris","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.3748\/wjg.v23.i11.1932","article-title":"Insights on the use of biosimilars in the treatment of inflammatory bowel disease","volume":"23","author":"Zheng","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrgastro.2016.155","article-title":"Biosimilars in IBD: From theory to practice","volume":"14","author":"Danese","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2017.04.002","article-title":"Association of Ribonuclease T2 Gene Polymorphisms With Decreased Expression and Clinical Characteristics of Severity in Crohn\u2019s Disease","volume":"153","author":"Gonsky","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"760","DOI":"10.2174\/1389450122999210120205607","article-title":"TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease","volume":"22","author":"Furfaro","year":"2021","journal-title":"Curr. Drug Targets"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"18189","DOI":"10.1038\/s41598-020-75168-5","article-title":"Direct signaling of TL1A-DR3 on fibroblasts induces intestinal fibrosis in vivo","volume":"10","author":"Jacob","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cgh.2021.06.011","article-title":"Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study","volume":"19","author":"Danese","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/ibd\/izab193","article-title":"Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis","volume":"28","author":"Ye","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/19420862.2018.1440164","article-title":"An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease","volume":"10","author":"Clarke","year":"2018","journal-title":"MAbs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41586-020-2796-5","article-title":"Integration of innate immune signalling by caspase-8 cleavage of N4BP1","volume":"587","author":"Gitlin","year":"2020","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s003840100340","article-title":"Systemic and local evidence of increased Fas-mediated apoptosis in ulcerative colitis","volume":"17","author":"Yukawa","year":"2002","journal-title":"Int. J. Color. Dis."},{"key":"ref_27","first-page":"411","article-title":"Adoptive Transfer of Dendritic Cells Expressing Fas Ligand Modulates Intestinal Inflammation in a Model of Inflammatory Bowel Disease","volume":"7","author":"Isidro","year":"2016","journal-title":"J. Clin. Cell. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1111\/jcmm.16459","article-title":"Osthole enhances the immunosuppressive effects of bone marrow\u2014Derived mesenchymal stem cells by promoting the Fas\/FasL system","volume":"25","author":"Yu","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.4049\/jimmunol.167.11.6330","article-title":"Constitutive Expression of LIGHT on T Cells Leads to Lymphocyte Activation, Inflammation, and Tissue Destruction","volume":"167","author":"Shaikh","year":"2001","journal-title":"J. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1053\/j.gastro.2014.02.010","article-title":"The Tumor Necrosis Factor Family Member TNFSF14 (LIGHT) Is Required for Resolution of Intestinal Inflammation in Mice","volume":"146","author":"Krause","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.cell.2018.08.067","article-title":"Structural Remodeling of the Human Colonic Mesenchyme in Inflammatory Bowel Disease","volume":"175","author":"Kinchen","year":"2018","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/s41385-019-0168-y","article-title":"TRAIL suppresses gut inflammation and inhibits colitogeic T-cell activation in experimental colitis via an apoptosis-independent pathway","volume":"12","author":"Chyuan","year":"2019","journal-title":"Mucosal Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/gutjnl-2019-319758","article-title":"Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: A prospective randomised trial","volume":"69","author":"Roblin","year":"2020","journal-title":"Gut"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/nyas.13414","article-title":"Biological and clinical implications of herbal medicine and natural products for the treatment of inflammatory bowel disease","volume":"1401","author":"Guo","year":"2017","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1089\/jmf.2020.0129","article-title":"Effects of the Use of Curcumin on Ulcerative Colitis and Crohn\u2019s Disease: A Systematic Review","volume":"24","author":"Goulart","year":"2021","journal-title":"J. Med. Food"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10787-017-0337-0","article-title":"The impact of mangiferin from Belamcanda chinensis on experimental colitis in rats","volume":"26","author":"Szandruk","year":"2018","journal-title":"Inflammopharmacology"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Du, Y., Ding, H., Vanarsa, K., Soomro, S., Baig, S., Hicks, J., and Mohan, C. (2019). Low Dose Epigallocatechin Gallate Alleviates Experimental Colitis by Subduing Inflammatory Cells and Cytokines, and Improving Intestinal Permeability. Nutrients, 11.","DOI":"10.3390\/nu11081743"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Liso, M., Sila, A., Verna, G., Scarano, A., Donghia, R., Castellana, F., Cavalcanti, E., Pesole, P.L., Sommella, E.M., and Lippolis, A. (2022). Nutritional Regimes Enriched with Antioxidants as an Efficient Adjuvant for IBD Patients under Infliximab Administration, a Pilot Study. Antioxidants, 11.","DOI":"10.3390\/antiox11010138"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: From discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.immuni.2019.06.008","article-title":"Temporally Distinct Functions of the Cytokines IL-12 and IL-23 Drive Chronic Colon Inflammation in Response to Intestinal Barrier Impairment","volume":"51","author":"Eftychi","year":"2019","journal-title":"Immunity"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: A multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1080\/14712598.2020.1792882","article-title":"Ustekinumab for treating ulcerative colitis: An expert opinion","volume":"20","author":"Biancone","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_45","first-page":"Cd012804","article-title":"Anti-IL-12\/23p40 antibodies for maintenance of remission in Crohn\u2019s disease","volume":"12","author":"Davies","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjac034","article-title":"Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention","volume":"16","author":"Sewell","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"101604","DOI":"10.1016\/j.bpg.2019.02.006","article-title":"IL12\/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn\u2019s disease?","volume":"38\u201339","author":"Ma","year":"2019","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"ii73","DOI":"10.1093\/ecco-jcc\/jjab190","article-title":"Personalised Medicine with IL-23 Blockers: Myth or Reality?","volume":"16","author":"Gottlieb","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn\u2019s disease: A randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/ecco-jcc\/jjab093","article-title":"Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn\u2019s Disease: Results from the Phase 2 Open-Label Extension Study","volume":"15","author":"Ferrante","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/ecco-jcc\/jjy099","article-title":"Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn\u2019s Disease: Results From a Randomised Phase II Biopsy Sub-study","volume":"12","author":"Visvanathan","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","article-title":"Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn\u2019s Disease: A Phase 2a Study","volume":"153","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cgh.2020.09.028","article-title":"Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"ii20","DOI":"10.1093\/ecco-jcc\/jjac023","article-title":"What Can IBD Specialists Learn from IL-23 Trials in Dermatology?","volume":"16","author":"Valenti","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/75068","article-title":"Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo","volume":"6","author":"Atreya","year":"2000","journal-title":"Nat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"eaaw2262","DOI":"10.1126\/sciimmunol.aaw2262","article-title":"T H 17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity","volume":"5","author":"Harbour","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/gutjnl-2017-314562","article-title":"Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn\u2019s disease (ANDANTE I and II)","volume":"68","author":"Danese","year":"2019","journal-title":"Gut"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cyto.2016.04.012","article-title":"Neutralization of IL-6 and TNF-\u03b1 ameliorates intestinal permeability in DSS-induced colitis","volume":"83","author":"Xiao","year":"2016","journal-title":"Cytokine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jnutbio.2017.01.012","article-title":"A food-based approach that targets interleukin-6, a key regulator of chronic intestinal inflammation and colon carcinogenesis","volume":"43","author":"Sido","year":"2017","journal-title":"J. Nutr. Biochem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/cts.13164","article-title":"Utilization of physiologically-based pharmacokinetic model to assess disease-mediated therapeutic protein-disease-drug interaction in immune-mediated inflammatory diseases","volume":"15","author":"Wang","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"102927","DOI":"10.1016\/j.autrev.2021.102927","article-title":"Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis","volume":"21","author":"Jena","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1053\/j.gastro.2021.02.062","article-title":"Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jcmgh.2022.03.003","article-title":"Interleukin 1\u03b2 Blockade Reduces Intestinal Inflammation in a Murine Model of Tumor Necrosis Factor\u2013Independent Ulcerative Colitis","volume":"14","author":"Liso","year":"2022","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes","volume":"378","author":"Gattorno","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.bbrc.2020.04.073","article-title":"Development and application of an antibody that binds to interleukin-1\u03b2 of various mammalian species for the treatment of inflammatory diseases","volume":"527","author":"Oh","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev.immunol.16.1.27","article-title":"Interleukin-1 Receptor Antagonist: Role in Biology","volume":"16","author":"Arend","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bcp.2018.06.029","article-title":"Therapeutic potential of dinitrobenzene sulfonic acid (DNBS)-induced colitis in mice by targeting IL-1\u03b2 and IL-18","volume":"155","author":"Impellizzeri","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1053\/j.gastro.2016.08.055","article-title":"Interleukin 1\u03b2 Mediates Intestinal Inflammation in Mice and Patients With Interleukin 10 Receptor Deficiency","volume":"151","author":"Shouval","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e023765","DOI":"10.1136\/bmjopen-2018-023765","article-title":"Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: The IASO trial","volume":"9","author":"Thomas","year":"2019","journal-title":"BMJ Open"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3389\/fcimb.2019.00365","article-title":"Definition of the Anti-inflammatory Oligosaccharides Derived From the Galactosaminogalactan (GAG) From Aspergillus fumigatus","volume":"9","author":"Gressler","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1124\/pharmrev.120.000171","article-title":"Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950","volume":"73","author":"Corcoran","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3389\/fphar.2018.01405","article-title":"A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation","volume":"9","author":"Pellegrini","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.molimm.2018.09.004","article-title":"Curcumin alleviates DSS-induced colitis via inhibiting NLRP3 inflammsome activation and IL-1\u03b2 production","volume":"104","author":"Gong","year":"2018","journal-title":"Mol. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: Immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.cell.2015.10.072","article-title":"Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis","volume":"163","author":"Nowarski","year":"2015","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9386","DOI":"10.1038\/s41598-019-45747-2","article-title":"Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: A Mendelian randomization study","volume":"9","author":"Mokry","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Wlodek, E., Kirkpatrick, R.B., Andrews, S., Noble, R., Schroyer, R., Scott, J., Watson, C.J.E., Clatworthy, M., Harrison, E.M., and Wigmore, S.J. (2021). A pilot study evaluating GSK1070806 inhibition of interleukin-18 in renal transplant delayed graft function. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247972"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/gutjnl-2014-308337","article-title":"Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: Efficacy and safety from a phase IIa randomised multicentre study","volume":"64","author":"Reinisch","year":"2015","journal-title":"Gut"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/gutjnl-2014-308004","article-title":"Tralokinumab for moderate-to-severe UC: A randomised, double-blind, placebo-controlled, phase IIa study","volume":"64","author":"Danese","year":"2015","journal-title":"Gut"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41598-019-57233-w","article-title":"Role of innate lymphoid cells in chronic colitis during anti-IL-17A therapy","volume":"10","author":"Park","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3389\/fimmu.2019.00459","article-title":"Combined IL-2 Immunocomplex and Anti-IL-5 mAb Treatment Expands Foxp3+ Treg Cells in the Absence of Eosinophilia and Ameliorates Experimental Colitis","volume":"10","author":"Abo","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1517\/14728222.2014.945426","article-title":"IL-21 as a therapeutic target in inflammatory disorders. Expert Opin","volume":"18","author":"Izzo","year":"2014","journal-title":"Ther. Targets"},{"key":"ref_87","first-page":"2764","article-title":"IL-33 Drives Expansion of Type 2 Innate Lymphoid Cells and Regulatory T Cells and Protects Mice From Severe, Acute Colitis","volume":"12","author":"Phuong","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"107859","DOI":"10.1016\/j.pharmthera.2021.107859","article-title":"Soluble ligands as drug targets for treatment of inflammatory bowel disease","volume":"226","author":"Tong","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-Stimulated Genes: A Complex Web of Host Defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Tindemans, I., Joosse, M.E., and Samsom, J.N. (2020). Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD. Cells, 9.","DOI":"10.3390\/cells9010110"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2021.07.026","article-title":"Systemic Inflammation in Preclinical Ulcerative Colitis","volume":"161","author":"Bergemalm","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1172\/JCI124884","article-title":"IFN-\u03b3 drives inflammatory bowel disease pathogenesis through VE-cadherin\u2013directed vascular barrier disruption","volume":"129","author":"Langer","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/ibd\/izaa216","article-title":"Type I and II Interferon Signatures Can Predict the Response to Anti-TNF Agents in Inflammatory Bowel Disease Patients: Involvement of the Microbiota","volume":"26","author":"Mavragani","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.chom.2021.04.004","article-title":"Western diet induces Paneth cell defects through microbiome alterations and farnesoid X receptor and type I interferon activation","volume":"29","author":"Liu","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.3389\/fimmu.2021.767505","article-title":"Interferon Lambda in the Pathogenesis of Inflammatory Bowel Diseases","volume":"12","author":"Wallace","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/gut.2005.079392","article-title":"Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn\u2019s disease","volume":"55","author":"Hommes","year":"2006","journal-title":"Gut"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","article-title":"Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis?","volume":"77","author":"Baker","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1038\/s41598-019-48331-w","article-title":"Berberine improved experimental chronic colitis by regulating interferon-\u03b3- and IL-17A-producing lamina propria CD4+ T cells through AMPK activation","volume":"9","author":"Takahara","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cgh.2021.02.043","article-title":"Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/apt.16955","article-title":"Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis","volume":"56","author":"Verstockt","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: Results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Sandborn","year":"2017","journal-title":"Gut"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.cgh.2020.10.025","article-title":"Real-World Effectiveness and Safety of Tofacitinib in Crohn\u2019s Disease and IBD-U: A Multicenter Study From the TROPIC Consortium","volume":"19","author":"Fenster","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.gastro.2015.10.046","article-title":"Leukocyte Trafficking to the Small Intestine and Colon","volume":"150","author":"Habtezion","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3389\/fimmu.2021.656452","article-title":"Targeting Immune Cell Trafficking\u2014Insights from Research Models and Implications for Future IBD Therapy","volume":"12","author":"Wiendl","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/med.21601","article-title":"The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti\u2014Integrin therapies","volume":"40","author":"Dotan","year":"2020","journal-title":"Med. Res. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nrm2871","article-title":"The final steps of integrin activation: The end game","volume":"11","author":"Shattil","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1136\/gutjnl-2015-310022","article-title":"Differential effects of \u03b14\u03b27 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo","volume":"65","author":"Fischer","year":"2016","journal-title":"Gut"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1172\/JCI116575","article-title":"Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody","volume":"92","author":"Podolsky","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"S653","DOI":"10.1093\/ecco-jcc\/jjy060","article-title":"Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease","volume":"12","author":"Lamb","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1053\/j.gastro.2015.08.044","article-title":"Safety and Efficacy of AJM300, an Oral Antagonist of \u03b14 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis","volume":"149","author":"Yoshimura","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S2468-1253(22)00022-X","article-title":"AJM300 (carotegrast methyl), an oral antagonist of \u03b14-integrin, as induction therapy for patients with moderately active ulcerative colitis: A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"7","author":"Matsuoka","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn\u2019s Disease: Results From the VISIBLE 2 Randomised Trial","volume":"16","author":"Vermeire","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5217\/ir.2018.00141","article-title":"Efficacy and safety of abrilumab, an \u03b14\u03b27 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: A phase II study","volume":"17","author":"Hibi","year":"2019","journal-title":"Intest. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1053\/j.gastro.2021.08.045","article-title":"PTG-100, an Oral \u03b14\u03b27 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis","volume":"161","author":"Sandborn","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(21)00298-3","article-title":"Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): A phase 3, randomised, controlled trial","volume":"7","author":"Hart","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S2468-1253(21)00294-6","article-title":"Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): A randomised, double-blind, double-dummy, phase 3 study","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1007\/s12325-020-01366-2","article-title":"The Etrolizumab Global Steering Committee Etrolizumab for the Treatment of Ulcerative Colitis and Crohn\u2019s Disease: An Overview of the Phase 3 Clinical Program","volume":"37","author":"Sandborn","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000500721","article-title":"Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More","volume":"4","author":"Schreiner","year":"2019","journal-title":"Inflamm. Intest. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/ibd\/izy077","article-title":"Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s","volume":"24","author":"Binder","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Roosenboom, B., van Lochem, E.G., Meijer, J., Smids, C., Nierkens, S., Brand, E.C., van Erp, L.W., Kemperman, L.G., Groenen, M.J., and Horje, C.S.H.T. (2020). Development of Mucosal PNAd+ and MAdCAM-1+ Venules during Disease Course in Ulcerative Colitis. Cells, 9.","DOI":"10.3390\/cells9040891"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/ecco-jcc\/jjab023","article-title":"Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II","volume":"15","author":"Reinisch","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1038\/s41467-021-25189-z","article-title":"ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer","volume":"12","author":"Taftaf","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fphar.2019.00314","article-title":"Oligonucleotides\u2014A Novel Promising Therapeutic Option for IBD","volume":"10","author":"Scarozza","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000484979","article-title":"Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis","volume":"36","author":"Greuter","year":"2018","journal-title":"Dig. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"a016303","DOI":"10.1101\/cshperspect.a016303","article-title":"The Chemokine System in Innate Immunity","volume":"7","author":"Sokol","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cyto.2015.10.008","article-title":"Chemokine and cytokine levels in inflammatory bowel disease patients","volume":"77","author":"Singh","year":"2016","journal-title":"Cytokine"},{"key":"ref_132","first-page":"603","article-title":"CCL20 Is Negatively Regulated by TGF-\u03b21 in Intestinal Epithelial Cells and Reduced in Crohn\u2019s Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide","volume":"11","author":"Marafini","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jaut.2017.10.013","article-title":"CCR6 signaling inhibits suppressor function of induced-Treg during gut inflammation","volume":"88","author":"Kulkarni","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"102846","DOI":"10.1016\/j.autrev.2021.102846","article-title":"CCR6-CCL20 axis as a therapeutic target for autoimmune diseases","volume":"20","author":"Meitei","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.1111\/jcmm.14686","article-title":"Taraxacum officinale extract ameliorates dextran sodium sulphate\u2014Induced colitis by regulating fatty acid degradation and microbial dysbiosis","volume":"23","author":"Chen","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.4049\/jimmunol.1501828","article-title":"A Small Molecule Inhibitor of ITK and RLK Impairs Th1 Differentiation and Prevents Colitis Disease Progression","volume":"195","author":"Cho","year":"2015","journal-title":"J. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3389\/fimmu.2018.02307","article-title":"An ROR\u03b3t Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn\u2019s Disease Patients","volume":"9","author":"Raymond","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/ecco-jcc\/jjv224","article-title":"Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study","volume":"10","author":"Sandborn","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/ecco-jcc\/jjx005","article-title":"Eldelumab [anti-interferon-\u03b3-inducible protein-10 antibody] Induction Therapy for Active Crohn\u2019s Disease: A Randomised, Double-blind, Placebo-controlled Phase IIa Study","volume":"11","author":"Sandborn","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1038\/s41388-021-02046-3","article-title":"CCL11 exacerbates colitis and inflammation-associated colon tumorigenesis","volume":"40","author":"Polosukhina","year":"2021","journal-title":"Oncogene"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000449077","article-title":"Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions","volume":"35","author":"Sands","year":"2017","journal-title":"Dig. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Cappenberg, A., Kardell, M., and Zarbock, A. (2022). Selectin-Mediated Signaling\u2014Shedding Light on the Regulation of Integrin Activity in Neutrophils. Cells, 11.","DOI":"10.3390\/cells11081310"},{"key":"ref_143","first-page":"147","article-title":"Soluble P-selectin glycoprotein ligand\u2014A possible new target in ulcerative colitis","volume":"116","author":"Ajdukovic","year":"2015","journal-title":"Bratisl. Lek. List."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e00298","DOI":"10.14309\/ctg.0000000000000298","article-title":"Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients with Inflammatory Bowel Disease: A 5-Year Clinical Follow-up","volume":"12","author":"Bravo","year":"2021","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.molmed.2017.02.002","article-title":"Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease","volume":"23","author":"Nielsen","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","article-title":"Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study","volume":"15","author":"Sandborn","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","article-title":"Ozanimod induction therapy for patients with moderate to severe Crohn\u2019s disease: A single-arm, phase 2, prospective observer-blinded endpoint study","volume":"5","author":"Feagan","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Shimano, K., Maeda, Y., Kataoka, H., Murase, M., Mochizuki, S., Utsumi, H., Oshita, K., and Sugahara, K. (2019). Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0226154"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/ecco-jcc\/jjab232.023","article-title":"A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn\u2019s Disease","volume":"16","author":"Danese","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.14309\/ajg.0000000000001261","article-title":"Progress in Corticosteroid Use in the Era of Biologics With Room for Improvement","volume":"116","author":"Abdalla","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.14309\/ajg.0000000000001220","article-title":"Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis","volume":"116","author":"Targownik","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nrgastro.2009.222","article-title":"Top-down therapy for IBD: Rationale and requisite evidence","volume":"7","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"ii54","DOI":"10.1093\/ecco-jcc\/jjac007","article-title":"IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality","volume":"16","author":"Atreya","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/s41395-018-0246-x","article-title":"Refocusing IBD Patient Management: Personalized, Proactive, and Patient-Centered Care","volume":"113","author":"Siegel","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4103\/CMAC.CMAC_8_21","article-title":"The Importance of Adopting Leadership Concepts in Communicating Medicinal Culture of Chinese Medicine in the Western World","volume":"4","author":"Wu","year":"2021","journal-title":"Chin. Med. Cult."},{"key":"ref_160","first-page":"1","article-title":"Drug discovery is an eternal challenge for the biomedical sciences","volume":"1","author":"Li","year":"2022","journal-title":"Acta Mater. Med."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/9\/1080\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:20:01Z","timestamp":1760142001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/9\/1080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":160,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ph15091080"],"URL":"https:\/\/doi.org\/10.3390\/ph15091080","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]}}}